How MLR Teams in Pharma Can Balance Compliance, Creativity and Speed

MLR teams play one of the most critical roles in pharma — yet their contribution rarely gets the recognition it deserves. More often, MLR is seen as the bottleneck: the stage where content slows down, gets stuck in endless revision loops, or dies altogether. Content writers and marketers regularly name it as their biggest frustration. However, done well, pharma approval workflows can be the foundation that makes content trustworthy enough to succeed. So how can MLR teams become genuine drivers of success rather than a checkpoint to survive? And what role is AI starting to play in getting them there? That’s what this article explores.

Who Are MLR Teams in Pharma?

MLR stands for Medical, Legal, and Regulatory, and all of these are different functions, each responsible for reviewing content for a different reason:

• Medical checks scientific accuracy and clinical claims.
• Legal checks intellectual property, contractual, and liability risk.
• Regulatory checks compliance with FDA/EMA/local health authority rules and label alignment.

Each discipline is protecting against a different kind of risk — clinical misstatement, legal liability, regulatory violation — and none of them can substitute for the others. MLR review is inherently slower than a single-reviewer sign-off, and this is not because of poor workflows or bureaucratic bloat.

MLR teams are the cross-functional review group responsible for approving all of the content produced by a company. Promotional materials, HCP-facing content, patient-facing content, digital/social assets, sales aids, congress materials, websites — basically anything a company puts into market that makes a claim about a product has to be first checked by MLR teams.

Why MLR Teams Are Under More Pressure Than Ever

Content demands are accelerating faster than most MLR teams in pharma can adjust. Rising volume, omnichannel speed expectations, and AI-driven personalization are converging all at once — and the traditional review model wasn’t built to absorb any of them, let alone all three together.

Rising content volume across channels

Pharma content and marketing teams are constantly put under a lot of pressure to create more, get published on multiple platforms, keep up with modern trends, and do a roster of many other things. Data shows content production rose 7% globally and 29% in the U.S. in 2023 over the prior year, with no signs of slowing — though notably, field teams rarely or never use 77% of their field content, which signals that the workflows are simply not ready for the volume of content that’s expected from pharma companies.

Faster omnichannel expectations

HCPs and patients now expect pharma brands to engage them quickly and consistently across every channel at once — email, rep visits, web portals, social, in-app messages — rather than through slow, siloed, one-channel-at-a-time communication.

With 84% of physicians preferring to maintain or increase the share of virtual interactions with pharma companies, the pressure has moved from just about being present across more channels to also being fast and relevant within the ones HCPs are already choosing.

AI and content personalization increase complexity

With content production scaling up by 10x or even 100x due to hyper-personalization, tools will be essential to streamline MLR review processes. However, giving AI tools to employees who aren’t prepared to use them can actually decrease performance rather than boost it — one of the biggest mistakes organizations make. AI-driven personalization doesn’t automatically reduce complexity — it can increase it if literacy and governance don’t scale alongside the tools.

The Traditional Problem with MLR Review in Pharma

The traditional model for the MLR review was built for a lower-volume, single-channel era — and it’s now colliding with the trends taking over the industry. Here are some of the biggest challenges that hamper progress and innovation within pharma:

Linear, sequential review

Traditionally, content moves through Medical, then Legal, then Regulatory (or some fixed order) — one reviewer at a time, each waiting on the last. A single round of feedback can take weeks; multiple rounds of revisions compound that into months.

Manual, repetitive checking

Reviewers manually scan for unapproved claims, missing references, off-label language — line by line, asset by asset — even when much of the content is nearly identical to something already approved. A tagline that’s been cleared a dozen times still gets flagged and re-checked from scratch, simply because no system remembers the prior approval.

Version chaos

Without centralized systems, tracking which claims/visuals/disclosures are actually approved becomes difficult, especially once content gets reused or repurposed across channels without a clear system of record.

Fragmented feedback loops

Comments and revisions often bounce between marketing, medical, and legal in disconnected threads (email, PDFs, meetings) rather than a single coordinated workflow — creating duplicate reviews and miscommunication rather than one clean pass.

What High-Performing MLR Teams Prioritize in 2026

Knowing what’s broken is the easy part. The harder question is what to actually fix first — and here, the teams pulling ahead of the pack tend to agree on a short list of priorities.

Risk reduction without blocking innovation

MLR exists to protect patients, but overly cautious review can become a growth bottleneck. Still, trying to optimize MLR only for the sake of speed is likely to result in jeopardized safety of patients and HCPs. For many pharma MLR teams, the goal has become not less scrutiny, but smarter scrutiny.

Scientific accuracy and context

As AI takes over more of the mechanical checking (references, claim-matching, missing citations), the differentiator between average and high-performing MLR teams stops being “did we catch the errors” — everyone with decent tooling can do that now. It becomes “did we get the context right,” because that’s the harder, judgment-dependent layer that AI can’t fully own.

Content reuse and modular approvals

Teams often resubmit nearly identical assets for full review, wasting reviewer time on things that were already approved elsewhere. Content modularization solves the problem by introducing a different mechanism: pre-approved modules (claims, visuals, disclaimers, references) get reviewed once, then reused across channels and campaigns — only new/changed pieces need re-review.

Faster review readiness through AI

The biggest speed gains come from catching problems before content reaches MLR, not from speeding up the review meeting itself. This is “shifting left”: fix issues early, where they’re cheap to correct, instead of at the review stage.

The teams pulling ahead go a step further, toward “compliance by design”: content authored directly from structured, pre-approved claims and references, so there’s less to catch at all. That’s the real gap between a team using AI as a faster patch and one that’s redesigned the process around it.

Compliance vs Creativity Is the Wrong Debate

Most teams treat MLR as a brake pedal on creative ideas. And when we happen to see a brand that moves very fast, we tend to think they are the ones with the loosest compliance. In reality, those brands are actually the ones who have managed to build compliance infrastructure based on both creativity and innovation.

• Where creativity actually dies isn’t compliance. If constraints are known upfront (via a claims library, pre-approved modules), creative teams can design within the guardrails from the start instead of hitting them at the end.
• Constraints often produce better creative work, not worse. Total freedom rarely produces the sharpest ideas — tight constraints force specificity and originality. In pharma, the constraint is fixed — so the creative skill is finding the most compelling way to say what is true.
• The real trade-off isn’t compliance vs. creativity. Teams that skip building good compliance infrastructure rarely get more creative freedom. What usually happens is late-stage rejections, which is slower and more demoralizing for creative teams than working within clear rules from day one.

Doing everything by the book can feel rigid and inhibiting. And it is true to some extent, but only when the teams behind compliance and content don’t work together to come up with a modern and flexible infrastructure, as it lets creative teams move faster and take more creative swings, because they’re not guessing at what will survive review.

How AI Is Changing the Role of MLR Teams

MLR review isn’t just pattern-matching against a rulebook — it requires judgment calls that carry legal and regulatory accountability. Someone has to weigh ambiguous claims against evolving regulations, interpret how a message will land with a specific audience, and ultimately sign off knowing they’re liable if it’s wrong. Here is how AI is changing MLR teams and how they work:

• From checker to editor/strategist. Reviewers used to spend hours hunting for unapproved claims or missing citations line by line. With AI pre-screening doing that first pass, the reviewer’s role shifts to judgment calls AI can’t make. According to McKinsey, some pharmaceutical companies have reduced regulatory submission timelines by 50–65% through AI-enabled automation and workflow redesign, freeing reviewers to spend that reclaimed time on judgment calls rather than line-by-line scanning.
• New responsibility: overseeing the AI, not just the content. Someone now has to own the claims library that AI is grounded in, validate that AI outputs are accurate, and catch AI’s own failure modes (hallucination, missing context, false positives that create “comment fatigue”).
• Earlier involvement in the content lifecycle. As “compliance by design” becomes the goal, MLR teams get pulled upstream — into claims-library curation, module approval, and content architecture — rather than only appearing at the end as gatekeepers. The role becomes more collaborative, less purely reactive.
• Accountability doesn’t move — it stays human. Regulators (FDA, EMA, ABPI Code) are explicit that AI cannot be the final approver of regulated content. So even as AI takes over volume, humans remain the ones who must review, interpret, and approve before anything goes live.
• The trust question is still live. Many MLR professionals remain skeptical of AI in this space, and that skepticism is itself shaping how the role evolves — toward transparency, audit trails, and explainability requirements rather than blind automation.

As AI absorbs repetitive checking, MLR teams may shrink in headcount-per-asset terms, but the remaining roles demand more scientific and strategic judgment, not less.

What Pharma Teams Should Do Next

The problems are clear. The fixes are not complicated — but they do require pharma teams to stop treating MLR as a bottleneck to survive and start treating it as a process to design. Here’s where to begin:

Audit your claims and reference library first

Before you purchase any tool or integrate any new systems, make sure you have a structured foundation first. AI-powered MLR checks and modular content will fail without a clean infrastructure. If the library’s a mess, any tool built on top of it inherits that mess. This is the natural “start here” advice.

Identify where content is duplicated, not where it’s slow

Many MLR teams in pharma think that the biggest problem is the reviews taking too much time. However, if they were to take a look at the matter from a different angle, they would notice that most problems stem from content being recreated and resubmitted multiple times. If content is near-identical to something already approved, it’s best to repurpose the old piece of content instead of creating something very similar.

Pilot AI pre-screening narrow before scaling wide

The phased rollout, despite taking more time, has been proven to be more effective than a launch of AI-powered tools across all areas right away. Start with one therapeutic area or market, run in parallel with the existing process for a few weeks, measure precision/recall honestly, then expand. Avoid the “AI demo excitement” trap of rolling out broadly before trusting the output.

Bring MLR into the room earlier, not just at the end

Compliance-by-design should be a main approach for pharma teams. Compliance should shape workflows from the start. Involving MLR and legal early, both in content development and in curating the claims library, helps determine how AI-powered workflows can fit into compliance rather than work around it.

Decide where humans stay irreplaceable — and protect that time

As AI takes the mechanical load off reviewers, teams should deliberately redirect that freed-up time toward context, nuance, and strategic judgment, rather than just using it to process more volume.

The pharma teams that win in 2026 won’t be the ones with the most content, or even the fastest reviews. Those who have rebuilt the foundation so speed and compliance stop being a trade-off will be able to withstand the challenges in the pharma industry and adopt AI in a way that advances innovation.

Bottom Line

MLR was never the enemy of speed or creativity — the old process just wasn’t built for the volume, channels, and personalization pharma is dealing with in 2026. Get that foundation right, and the debate changes entirely. Compliance stops being a brake on content and becomes what lets teams move faster, personalize more, and take bigger creative swings — because they know exactly where the guardrails are before they start building.

If you are looking for a solution that helps companies build efficient MLR workflows that don’t hinder content creation and allow for freedom of creativity, contact our team. We will set up a free call where we will discuss all possible solutions that are suitable for you.